FSH | Normal | Abnormal |
---|---|---|
n (%) | n (%) | |
Patients | 10 (26) | 28 (74) |
Age at HCT, yr | 8.6 ± 1.3 | 8.1 ± 0.6 |
Age at evaluation, yr | 15.8 ± 0.5 | 16.7 ± 0.4 |
Interval between HCT and evaluation, yr | 7.3 ± 1.5 | 8.6 ± 0.6 |
Conditioning | ||
TBI | 8 (23) | 26 (77) |
TLI | 1 (33) | 2 (67) |
Chemotheray alone | 1 | |
Cyclophosphamide | +9 (45) | 11 (55) |
-1 (5) | 17 (95) | |
Busulfan | +1 (100) | |
-9 (24) | 28 (76) | |
Melphalan | +0 | 16 (100) |
-10 (45) | 12 (55) | |
Inhibin B, pg/mL | 202 ± 58 | 35 ± 5* |
n = 10 | ||
Tubular failure, n = 16 | ||
47 ± 7** | ||
Tubular and Leydig cell failures, n = 12 | ||
20 ± 3 | ||
AMH, pmol/L | 195 ± 86 | 41 ± 6*** |
n = 8 | ||
Tubular failure, n = 14 | ||
51 ± 7**** | ||
Tubular and Leydig cell failures, n = 9 | ||
24 ± 6 |